All posts by: Michael Zand

Stem cell agency eyes kidney transplant breakthrough – Capitol Weekly

Capitol WeeklyStem cell agency eyes kidney transplant breakthroughCapitol WeeklyThe award brings to 44 the number of clinical trials being assisted by the $3 billion agency, formally known as the California Institute for Regenerative Medicine(CIRM). Cl… Continue reading

Byers Distinguished Professorship Awarded to Wendell Lim, Chair of Cellular and Molecular Pharmacology – UCSF News Services

UCSF News ServicesByers Distinguished Professorship Awarded to Wendell Lim, Chair of Cellular and Molecular PharmacologyUCSF News ServicesThe students worked with researchers to design and implement a project in synthetic biology and then entered their… Continue reading

China Has Already Gene-Edited 86 People With CRISPR – Gizmodo

Gizmodo

China Has Already Gene-Edited 86 People With CRISPR Gizmodo In China’s 2015 CRISPR trial, the WSJ reports, 36 patients with cancers of the kidney, lung, liver and throat had cells removed from their bodies, altered with CRISPR, and then infused back into their bodies to fight the cancer. Other Chinese trials … Nonviral Gene Therapy Platform Delivers CRISPR/Cas9 to TumorsGenetic Engineering & Biotechnology News European Court Supports the Softening of CRISPR Gene Editing RulesLabiotech.eu (blog) CRISPR gene editing may have just become a whole lot more accurateDigital Trends Phys.Org all 5 news articles »

Immuno-Oncology News

Rare Melanoma Responds Well to Immunotherapy Despite Thoughts It Wouldn’t, Study Reports Immuno-Oncology News A rare type of malignant melanoma is treatable with immunotherapies, according to a new study — overturning previous beliefs that the cancer, called desmoplastic melanoma, is not treatable with such medications. The specific treatments used prevent …

Excitement for CRISPR GenomeWeb Reddit users asked dozens of questions about CRISPR gene editing of members of Jennifer Doudna’s lab at the University of California, Berkeley, and of National Human Genome Research Institute officials. In the ‘Ask Me Anything’ held on the science sub …

TheStreet.com

Immunotherapy Stocks Power Higher on Celgene-Juno Deal TheStreet.com Immunotherapy Stocks Power Higher on Celgene-Juno Deal. Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics’ announced sale to Celgene. ByArmie Margaret Lee. Jan 22 …